Published in final edited form as:

Crit Rev Immunol. 2018 ; 38(3): 233–243. doi:10.1615/CritRevImmunol.2018026150.

Connection between $\gamma\delta$ T-cell– and Adenosine-Mediated Immune Regulation in the Pathogenesis of Experimental Autoimmune Uveitis

Dongchun Liang^a, Hui Shao^b, Willi K. Born^c, Rebecca L. O'Brien^c, Henry J. Kaplan^b, and Deming Sun^{a,*}

^aDoheny Eye Institute and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California

^bDepartment of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky

^cDepartment of Biomedical Research, National Jewish Health, Denver, Colorado

Abstract

Regulatory effects of $\gamma\delta$ T-cells on immune responses have been studied for years. We have investigated the regulatory effect of $\gamma\delta$ T-cells on Th1 and Th17 autoimmune responses, and have studied molecular and cellular mechanisms by which $\gamma\delta$ T-cells enhance or inhibit immune responses, exploiting a well-characterized murine model of experimental autoimmune uveitis (EAU). Our results show that (1) aberrant $\gamma\delta$ T-cell activation is an important pathogenic event in EAU; (2) $\gamma\delta$ T-cells have a unique regulatory effect on Th17 autoimmune responses, which is shaped by the activation status of $\gamma\delta$ T-cells; and (3) $\gamma\delta$ -mediated immunoregulation is closely linked with the extracellular adenosine metabolism. Reciprocal interactions between $\gamma\delta$ T-cells and extracellular adenosine partially determine the development of EAU.

Keywords

adenosine deaminase (ADA); autoimmunity; adenosine receptors; experimental autoimmune uveitis; Foxp3; $\gamma\delta$ T-cell; regulatory T-cell; Th17; uveitis

I. INNATE IMMUNITY IN AUTOIMMUNE DEVELOPMENT

Recent studies have shown that an effective immune response requires a coordinated interaction between innate and adaptive immunity.^{1–6} A rapid innate immune response not only fills the gap in immunologic defense before a fully effective adaptive response is generated; it also determines the pattern and intensity of the subsequent adaptive responses.^{5–7}

*Address all correspondence to: Deming Sun, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA 90033; Tel.: 323-342-6678, Dsun@doheny.org.

$\gamma\delta$ T-cells as cellular elements of innate immunity constitute less than 1% of the total lymphocytes in the periphery, but during infection or inflammation their numbers rapidly and dramatically expand within a few days.⁸ In mice induced for experimental autoimmune uveitis (EAU), a large portion (> 60%) of peripheral $\gamma\delta$ T-cells became activated in early preclinical phases of the disease (one week before its clinical appearance) and subsequently became a strong driving force of induced mouse EAU.^{9–11}

Adenosine and its derivatives modulate many physiological processes, including innate and adaptive immunity. Extracellular adenosine levels are low in healthy individuals,¹² but increase 100- to 1000-fold during tissue injury and inflammation.¹³ Adenosine reduces inflammation and tissue injury^{14–17} by acting on four different types of adenosine receptor (AR): A1R, A2AR, A2BR, and A3R.^{13,14} Adenosine is profoundly anti-inflammatory,^{14–19} whereas both ATP and ADP are highly proinflammatory.^{20–25} Intracellular concentrations of ATP are typically 10⁴-fold higher than extracellular concentrations.²⁶ Under physiological conditions, extracellular ATP (eATP) concentration is kept in the nanomolar range (1–100 nM). During tissue damage, such as ischemia, eATP levels can be elevated by thousands-fold.^{27,28} Studies have shown that elevated amounts of eATP trigger immune responses and function as a danger signal that activates the immune system.^{22–25} Therefore, eATP is considered proinflammatory— not only by stimulating innate immune responses, but also by favoring effector T-cell activation. Our results have demonstrated that regulation of $\gamma\delta$ T-cells in adaptive autoimmunity is associated with adenosine. Hence, a better understanding of the cellular and molecular mechanisms of the interactions between innate and adaptive immunity should allow us to manipulate the specific adaptive immune response more effectively; a rational therapeutic approach needs to take into account the balance between the two types of immune response.

II. REGULATORY EFFECT OF $\gamma\delta$ T-CELLS IN AUTOIMMUNE DISEASES

The regulatory effect of $\gamma\delta$ T-cells on immune responses has long been acknowledged. Studies have shown that $\gamma\delta$ T-cells can either upregulate^{29–32} or downregulate^{33–35} an immune response. This functional diversity was once attributed to different $\gamma\delta$ T-cell subsets expressing distinct T-cell receptors (TCRs).^{36–40} Studies also demonstrated that the regulatory activity of $\gamma\delta$ T-cells could be shaped by exposure to Toll ligands⁴¹ or mycobacteria.⁴² Clinical approaches have been developed to use $\gamma\delta$ T-cells as a potential therapeutic modality for cancers⁴³ and infections^{3,4}; however, limited knowledge of their regulatory mechanisms hampers an effective therapeutic application. Our studies using an established EAU model have repeatedly shown that the regulatory ability of $\gamma\delta$ T-cells is determined by their activation status and is more effective toward Th17-type than Th1-type immune responses.^{10,11,44–45} Hence, modulation of $\gamma\delta$ T-cell activation status significantly affects immune responses.

III. TH1 AND TH17 PATHOGENIC RESPONSES IN THE PATHOGENESIS OF EAU

Over the past three decades, circumstantial evidence has supported the notion that a major subset of pathogenic T-cells in autoimmune diseases produces IFN- γ and IL-2 and belongs

to the Th1 CD4 T-cell family.^{46–53} Recent studies have shown, however, that Th17 cells, which characteristically produce interleukin (IL-) –17A, IL-17F, IL-21, and IL-22, are another major subset of pathogenic T-cells. The finding that Th17 autoreactive T-cells are an important pathogenic T-cell subset in autoimmune diseases^{54–56} raised the question of whether they differ from the previously characterized Th1 autoreactive T-cells in pathogenesis^{57–61} and regulation.^{62,63} On the other hand, studies from transgenic animals have demonstrated that animals can keep autoaggression in check, even in the face of huge numbers of self-reactive cells,^{64,65} suggesting that the damaging effect of autoreactive T-cells must be balanced by a counter-reactive regulatory mechanism. Indeed, an aberrant immune response is frequently associated with regulatory cell dysfunction or an imbalance between regulatory and effector T-cells.^{66,67} Therefore, extensive studies have investigated how a healthy regulatory cell function is produced and maintained, what causes the imbalance between regulatory and effector T-cells during disease, and what treatment can restore normal functioning. T-cells expressing Foxp3 have been well characterized as major regulatory cells for Th1 responses, but their effectiveness in Th17 autoimmune responses has been questioned.^{62,63} Recent findings by our lab^{9,10,68,69} and others^{1,41,70,71} demonstrated that $\gamma\delta$ T-cells have a strong regulatory effect on various, including autoimmune, diseases. Some questions arise: (1) Does $\gamma\delta$ T-cell regulation of a given immune response differ from that of its regulation by $\alpha\beta$ T-cells? (2) What are the key factors that determine the regulatory effect of $\gamma\delta$ T-cells? And (3) What is the cellular and molecular basis of regulation by $\gamma\delta$ T-cells in Th1 and Th17 autoreactive responses?

IV. ACTIVATION STATUS DETERMINES THE ENHANCING ACTIVITY OF $\gamma\delta$ T-CELLS

One effective way to determine the regulatory effect of $\gamma\delta$ T-cells is to compare immune responses between wild-type (WT) C57BL/6 (B6) and genetically compatible TCR- $\delta^{-/-}$ mice, which heritably lack the ability to develop $\gamma\delta$ T-cells. Comparison of Th1 and Th17 autoimmune responses in immunized mice, including TCR- $\delta^{-/-}$ mice injected with an effective dose of $\gamma\delta$ T-cells, allowed us to define the role of $\gamma\delta$ T-cells in the regulation of immune responses. About a week after immunization, approximately 60% of the $\gamma\delta$ T-cells found in the periphery of EAU-prone B6 mice expressed CD69 and CD44, whereas $\gamma\delta$ T-cells of nonimmunized B6 mice rarely did so. Highly enriched $\gamma\delta$ T-cells exert widely different effects on autoreactive $\alpha\beta$ T-cells in EAU, depending on their activation status. Whereas nonactivated $\gamma\delta$ T-cells (isolated from naïve B6 mice) had little effect on the activation of IRBP-specific $\alpha\beta$ T-cells *in vitro* and *in vivo*, activated $\gamma\delta$ T-cells (isolated from immunized or naïve B6 mice that had been stimulated with antiCD3 antibodies for two days) promoted generation of uveitogenic T-cells and exacerbated EAU development.^{10,11,72} Similarly, TCR- $\delta^{-/-}$ mice injected with activated $\gamma\delta$ T-cells generated an approximately fourfold higher percentage of IL-17⁺ IRBP-specific $\alpha\beta$ T-cells by comparison with mice that received no injection or those injected with resting $\gamma\delta$ T-cells. Notably, when adoptively transferred to naïve recipients, IRBP-specific T-cells from mice injected with activated $\gamma\delta$ T-cells, but not from those injected with resting $\gamma\delta$ T-cells, induced more severe EAU.

V. MOLECULAR MECHANISM BY WHICH $\gamma\delta$ T-CELLS REGULATE TH17 CELLS

To determine whether the enhancing functions of $\gamma\delta$ T-cells are associated with the expression of specific surface molecules, and to determine the underlying mechanism by which $\gamma\delta$ cells switch their regulatory function, we examined a series of molecules that are differentially expressed on activated versus nonactivated $\gamma\delta$ T-cells. We were able to show that, in addition to expressing increased amounts of T-cell activation markers such as CD69, CD44, and CD25, activated $\gamma\delta$ T-cells express greatly increased levels of the adenosine A2A receptor (A2AR), which confers on them a greatly increased ability to bind adenosine when compared to other immune cell types such as $\alpha\beta$ T-cells and dendritic cells (DCs).^{45,73} Interestingly, ligation of A2AR-enhanced $\gamma\delta$ T-cell activation, whereas it inhibited activation of $\alpha\beta$ T-cells.^{73,74} Thus, expression of increased amounts of A2AR enables activated $\gamma\delta$ T-cells to bind adenosine more effectively and thereby attenuate adenosine's suppressive effect on $\alpha\beta$ T-cells. Moreover, compared to resting cells, activated $\gamma\delta$ T-cells express significantly lower levels of CD73,^{45,73} an enzyme involved in the generation of extracellular adenosine.^{18,75–78} Decreased expression of CD73 results in reduced generation of adenosine at the inflammatory site. Since both A2AR and CD73 molecules are crucially involved in metabolism, function, and the regulatory effect of extracellular ATP and adenosine,^{12,13,18} we wondered whether the altered expression of adenosine-related functional molecules accounts for the altered regulatory function of activated $\gamma\delta$ T-cells.^{45,73,74,79}

VI. ROLE OF ADENOSINE IN $\gamma\delta$ ACTIVATION AND REGULATION

ATP is dephosphorylated to ADP, AMP, and, ultimately, adenosine.^{12,80} CD39 and CD73 are two well-characterized ectoenzymes involved in the conversion of ATP to adenosine.^{75,76} The ecto-5-nucleotide enzyme CD73 is pivotal in the conversion of immunostimulatory ATP into immunosuppressive adenosine by conversion of eATP to adenosine.^{75,76} Studies have shown that T-cells expressing higher levels of CD39 and CD73 suppress inflammatory responses through the production of adenosine.^{16,17} Note that various immune cells are rich sources of extracellular adenosine, including B-cells,⁸¹ neutrophils,⁸² mast-cells,¹⁵ endothelial cells,^{82,83} and T-cells.¹³ Adenosine affects the functions of many cell types, including T-cells,^{77,84} macrophages/DCs,^{16,84,85} NK cells,⁸⁶ neutrophils,⁸⁷ platelets,⁸⁸ and regulatory T-cells (Tregs).^{16,17,89} Since adenosine affects Treg functions,^{17,89–91} we wished to determine whether it also affects the regulatory function of $\gamma\delta$ T-cells. Moreover, even though $\gamma\delta$ T-cells are a major cell element in inflamed organs and tissues,^{92–94} the connection between adenosine and $\gamma\delta$ T-cells has remained largely unknown.

$\gamma\delta$ T-cells can be activated via multiple pathways, such as cytokines and TLR ligands,^{95–98} even in the absence of $\gamma\delta$ TCR ligation. We were able to show that purified $\gamma\delta$ T-cells can be activated by a number of proinflammatory cytokines, and that a mixture of IL-1, IL-7, and IL-23 has a strong stimulatory effect.¹¹ Although adenosine does not directly stimulate $\gamma\delta$ T-cell activation, it significantly enhances activation induced by the cytokine mixture, an effect that can be blocked by the A2AR antagonist.⁷³ This activation of $\gamma\delta$ T-cells leads to

augmented Th17 responses,^{10,11,45} and the net effect of adenosine in Th17 responses is enhancing whereas its effect on Th1 response is mainly suppressive.^{16,45,99–103} The fact that adenosine inhibits Th1 autoreactive T-cell response but enhances $\gamma\delta$ T-cell and Th17 autoreactive T-cell response reveals that this molecule plays an important role in switching and balancing between Th1 and the Th17 responses in autoimmune pathogenesis.^{73,74,79}

VII. $\gamma\delta$ T-CELLS ACTIVELY PARTICIPATE IN THE CONVERSION OF EXTRACELLULAR ATP TO ADENOSINE

Our studies demonstrated that adenosine-mediated immunoregulation and $\gamma\delta$ T-cell-mediated immunoregulation are intimately linked in EAU pathogenesis. In addition to the fact that adenosine affects the activation of $\alpha\beta$ and $\gamma\delta$ T-cells, $\gamma\delta$ T-cells strongly influence extracellular ATP metabolism and adenosine generation^{73,79} as well as adenosine function.^{45,73,74,79} As we reported previously,¹⁰⁴ CD73⁺ $\gamma\delta$ T-cells are much more potent in converting AMP to adenosine compared to other CD73⁺ immune cells, including Foxp3⁺ $\alpha\beta$ T-cells when tested in the pathogenesis of mouse EAU.^{45,73}

Moreover, $\gamma\delta$ T-cells express different amounts of CD73 during the different stages of EAU.⁴⁵ Changes in the expressed level of CD73 are correlated with the “switch” of pro- to anti-inflammatory activities of $\gamma\delta$ T-cells in the regulation of Th17 autoimmune responses,⁴⁵ and low CD73 expression on $\gamma\delta$ T-cells favors their enhancing effect on Th17 autoimmune responses.⁴⁵ These results suggest the possibility of modulating Th17 autoimmune responses by manipulating CD73 expression on $\gamma\delta$ T-cells.

VIII. ROLE OF CD73 IN $\gamma\delta$ T-CELLS' REGULATORY FUNCTION

CD39 and CD73 in combination degrade ATP, ADP, and AMP to adenosine and have been viewed as “immunological switches” that shift ATP-driven proinflammatory immune cell activity toward an anti-inflammatory state mediated by adenosine.⁷⁶ Reduced CD73 expression decreases the conversion of AMP to adenosine, thus contributing to immune activation,¹⁰⁵ whereas cells that express higher levels of CD39 and CD73 may act to suppress inflammatory responses through the production of adenosine.^{16,17}

Alteration of the CD39/CD73 machinery can disrupt the complex mechanisms underlying immune tolerance to self-antigens, driven mainly by Tregs, thus contributing to the development of several autoimmune diseases.¹⁰⁶ It has been reported that CD39 is expressed on human and murine Tregs but that CD73 is found on the surface of murine Tregs only.^{90,107} Increased ATP-metabolizing activity appears to be critical for Treg immunosuppressive activity.¹⁰⁸

IX. ROLE OF EXTRACELLULAR ATP/ADENOSINE METABOLISM AND ADENOSINE-MEDIATED IMMUNOREGULATION IN $\gamma\delta$ REGULATION

We previously reported that CD73⁺ $\alpha\beta$ T-cells possess limited ability to convert AMP to adenosine as compared to CD73⁺ $\gamma\delta$ T-cells,⁷³ suggesting that the latter are the preeminent adenosine-converting cells among CD73⁺ immune cells.^{45,73} Moreover, $\gamma\delta$ T-cells express

different amounts of CD73 during the different stages of EAU, and the enhancing activity of $\gamma\delta$ T-cells correlate with decreased expression of CD73. $\gamma\delta$ T-cells express different amounts of CD73 when activated by different pathways, enabling them to either enhance or inhibit an adaptive immune response.^{45,73} Thus, activation of $\gamma\delta$ T-cells alters not only adenosine-mediated immunoregulation but also adenosine metabolism. Our studies on isolated $\gamma\delta$ T-cells from CD73^{+/+} (WT-B6) and CD73^{-/-} mice showed that failure to express CD73 greatly reduces both the enhancing and suppressive activities of $\gamma\delta$ T-cells^{45,73}; low CD73 expression on $\gamma\delta$ T-cells correlates with enhanced Th17 response-promoting activity; and CD73 expressed on $\gamma\delta$ T-cells is more functionally active than that expressed on $\alpha\beta$ T-cells. Thus, ATP/adenosine metabolism plays a significant role in the interconversion of the enhancing and suppressive effects of $\gamma\delta$ T-cells, and CD73 expressed by $\gamma\delta$ T-cells is important in this process. These results demonstrate that the mechanisms involved in the proinflammatory effect of activated $\gamma\delta$ T-cells in Th17-mediated autoimmune responses include both binding of adenosine by activated $\gamma\delta$ T-cells and decreased CD73 expression on activated $\gamma\delta$ T-cells. Further studies on the role of adenosine in inflammation and immune responses should result in improved immunotherapies based on adenosine and $\gamma\delta$ T-cells.

X. ACTIVATED $\gamma\delta$ T-CELLS ENHANCE IMMUNE RESPONSES BY EXPRESSION OF HIGH LEVELS OF A2AR

Extracellular adenosine, acting via A2AR, is an important negative regulator of T-cell development and function.^{14,16,17,77} The importance of A2AR in mediating immunoregulation has been demonstrated in A2AR-deficient (A2AR^{-/-}) mice, whose inability to control inflammation leads to fatal tissue destruction.^{14,109} Adenosine generated in injured tissue is destroyed by enzymes, mainly adenosine deaminase (ADA). Serum adenosine levels are significantly increased in ADA^{-/-} mice, whereas levels of downstream products of ADA-mediated adenosine conversion, such as hypoxanthine, are significantly reduced.¹¹⁰ Mice genetically deficient in ADA display altered inflammation.^{14,109} Immune dysfunction, including autoimmune and allergic diseases, has been frequently observed in humans and rodents with ADA dysfunction.^{111,112}

Many immune cell types have been studied in an effort to determine which is most affected by adenosine; these include T-cells,^{77,84,113–115} macrophages/DCs,^{16,116,117} NK cells,⁸⁶ neutrophils,^{87,118} platelets,⁸⁸ and Tregs.^{16,17,89} To determine whether A2AR is instrumental in the regulatory function of $\gamma\delta$ T-cells, we isolated $\gamma\delta$ T-cells from A2AR^{-/-} (A2AR^{-/-} $\gamma\delta$) and B6 mice (A2AR^{+/+} $\gamma\delta$), and compared their enhancing and inhibiting function. We were able to show that A2AR^{-/-} $\gamma\delta$ T-cells lose their Th17-enhancing activity; likewise, A2AR^{+/+} $\gamma\delta$ T-cells lose their Th17-enhancing activity after treatment with an A2AR antagonist, suggesting that expression of increased amounts of A2AR allows $\gamma\delta$ T-cells to bind adenosine and thereby attenuate its suppressive effect.

Comparisons between activated and nonactivated $\gamma\delta$ T-cells showed that activated $\gamma\delta$ T-cells expressed greatly increased levels of A2AR in addition to increased amounts of T-cell activation markers such as CD69, CD44, and CD25.⁷³ Importantly, using a binding assay,

we were able to show that activated $\gamma\delta$ T-cells bind far more adenosine than other immune cells.⁷³ Increased expression of adenosine A2AR allows $\gamma\delta$ T-cells to competitively bind adenosine in inflamed tissue, thus preventing its suppressive effect on $\alpha\beta$ T-cells. A strong binding of adenosine by activated $\gamma\delta$ T-cells represents more than a “sink”; for example, it enhances $\gamma\delta$ activation and the expression of A2AR increases $\gamma\delta$ activation,⁷³ rendering them more competitive in adenosine binding. Since activated $\gamma\delta$ T-cells have a strong ability to enhance Th17 response, their binding of adenosine may also weaken the suppressive effect of adenosine on $\alpha\beta$ T-cells, leading to enhanced immune response.^{45,73} Our finding, that the effect of A2AR agonist on $\gamma\delta$ T-cells is stimulatory rather than inhibitory, seems opposite to others’ findings concerning A2AR agonists on other immune cells,^{3,6,9–11} which is attributed to the high levels of A2AR in $\gamma\delta$ T-cells. Expression of increased amounts of A2AR likely allows $\gamma\delta$ T-cells to bind adenosine and thereby attenuate its suppressive effect.

XI. CONCLUDING REMARKS

The orchestration and modulation of inflammatory response in injured tissues by a number of regulatory mechanisms is quite sophisticated. Our studies showed that $\gamma\delta$ T-cells have a strong regulatory effect on autoimmune responses, particularly Th17 types. Whereas the regulatory effect of $\gamma\delta$ T-cells and that of extracellular ATP/adenosine metabolism in immune responses are well known, their intimate connection has yet to be completely elucidated and the cellular and molecular basis of this type of regulation has remained mostly unclear. We have made progress by demonstrating that $\gamma\delta$ -mediated and adenosine-mediated immunoregulation are intimately linked. The outcome of studies such as ours should improve current available therapies, including those based on adenosine and $\gamma\delta$ T-cell.

The studies summarized here are mostly derived from observations in a EAU mouse model, in which a dominant $V\gamma 4^+$ $\gamma\delta$ T-cell response is noted,^{44,68} whereas in this experimental model $V\gamma 1^+$ $\gamma\delta$ T-cells remain mostly nonactivated.⁴⁴ Given that $V\gamma 1^+$ $\gamma\delta$ T-cells are dominantly activated in many infectious disease models,^{119–124} and the dominant responses of $\gamma\delta$ T-cell subsets expressing distinct TCR segments remain unclarified, further studies should determine whether all $\gamma\delta$ T-cell subsets work essentially in the same way.

ACKNOWLEDGMENTS

Our research was supported by the National Institutes of Health Grants EY0022403 and EY018827, and by Research to Prevent Blindness, New York, New York.

ABBREVIATIONS:

ADA	adenosine deaminase
A2AR	adenosine A2A receptor
AR	adenosine receptor
EAU	experimental autoimmune uveitis

eATP	extracellular ATP
IRBP	interphotoreceptor retinoid-binding protein

REFERENCES

- Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S, Prinz I, Hemmer B, Kuchroo VK, Oukka M, Korn T. T-cells enhance autoimmunity by restraining regulatory T-cell responses via an interleukin-23-dependent mechanism. *Immunity*. 2010;33: 351–363. [PubMed: 20832339]
- Do J-S, Visperas A, Dong C, Baldwin WM, III, Min B. Cutting edge: generation of colitogenic Th17 CD4 T-cells is enhanced by IL-17+ $\gamma\delta$ T-cells. *J Immunol*. 2011;186:4546–50. [PubMed: 21402889]
- Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. *Science*. 2002;296:298–300. [PubMed: 11951031]
- Dieli F, Caccamo N, Meraviglia S, Ivanyi J, Sireci G, Bonanno CT, Ferlazzo V, Mendola C, Salerno A. Reciprocal stimulation of T-cells and dendritic cells during the anti-mycobacterial immune response. *Eur J Immunol*. 2004;34:3227–35. [PubMed: 15376192]
- Kim MS, Yan J, Wu W, Zhang G, Zhang Y, Cai D. Rapid linkage of innate immunological signals to adaptive immunity by the brain-fat axis. *Nat Immunol*. 2015;16: 525–33. [PubMed: 25848866]
- Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. *Nat Immunol*. 2015;16:343–53. [PubMed: 25789684]
- Vantourout P, Hayday A. Six-of-the-best: unique contributions of T-cells to immunology. *Nat Rev Immunol*. 2013;13:88–100. [PubMed: 23348415]
- Rajan AJ, Asensio VC, Campbell IL, Brosnan CF. Experimental autoimmune encephalomyelitis on the SJL mouse: effect of T-cell depletion on chemokine and chemokine receptor expression in the central nervous system. *J Immunol*. 2000;164:2120–30. [PubMed: 10657666]
- Spahn TW, Issazadah S, Salvin A., Weiner HL. Decreased severity of myelin oligodendrocyte glycoprotein peptide 33–35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR chain gene. *Eur J Immunol*. 1999;29:4060–71. [PubMed: 10602017]
- Odyniec A, Szczepanik M, Mycko MP, Stasiolek M, Raine CS, Selmaj KW. T-cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production. *J Immunol*. 2004;173: 682–94. [PubMed: 15210832]
- Tagawa T, Nishimura H, Yajima T, Hara H, Kishihara K, Matsuzaki G, Yoshino I, Maehara Y, Yoshikai. V1+ T-cells producing CC chemokines may bridge a gap between neutrophils and macrophages in innate immunity during *Escherichia coli* infection in mice. *J Immunol*. 2004;173:5156–64. [PubMed: 15470060]
- Tsuchiya T, Fukuda S, Hamada H, Nakamura A, Kohama Y, Ishikawa H, Tsujikawa K, Yamamoto H. Role of T-cells in the inflammatory response of experimental colitis mice. *J Immunol*. 2003;171:5507–13. [PubMed: 14607957]
- Uezu K, Kawakami K, Miyagi K, Kinjo Y, Kinjo T, Ishikawa H, Saito A. Accumulation of T-cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with *Cryptococcus neoformans*. *J Immunol*. 2004;172:7629–34. [PubMed: 15187143]
- D'Souza CD, Cooper AM, Frank AA, Mazzaccaro RJ, Bloom BR, Orme IM. An anti-inflammatory role for T lymphocytes in acquired immunity to *Mycobacterium tuberculosis*. *J Immunol*. 1997;158:1217–21. [PubMed: 9013962]
- Dalton JE, Pearson J, Scott P, Carding SR. The interaction of T-cells with activated macrophages is a property of the V1 subset. *J Immunol*. 2003;171:6488–94. [PubMed: 14662848]
- Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. Patterns of chemokine receptor expression on peripheral blood T lymphocytes: strong expression of CCR5 is a selective feature of V2/V9 T-cells. *J Immunol*. 2002;168:4920–9. [PubMed: 11994442]
- Hahn YS, Taube C, Jin N, Sharp L, Wands JM, Aydinug MK, Lahn M, Huber SA, O'Brien RL, Gelfand EW, Born WK. Different potentials of T-cell subsets in regulating airway responsiveness:

- V1+ cells, but not V4+ cells, promote airway hyperreactivity, Th2 cytokines, and airway inflammation. *J Immunol.* 2004;172:2894–902. [PubMed: 14978091]
18. Huber SA, Graveline D, Newell MK, Born WK, O'Brien RL. V1+ T-cells suppress and V4+ T-cells promote susceptibility to coxsackievirus B3-induced myocarditis in mice. *J Immunol.* 2000;165:4174–81. [PubMed: 11035049]
 19. O'Brien RL, Yin X, Huber SA, Ikuta K, Born WK. Depletion of a T-cell subset can increase host resistance to a bacterial infection. *J Immunol.* 2000;165:6472–9. [PubMed: 11086087]
 20. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating T-cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. *Immunity.* 2007;27:334–48. [PubMed: 17656116]
 21. Spencer CT, Abate G, Blazevic A, Hoft DF. Only a subset of phosphoantigen-responsive T-cells mediate protective tuberculosis immunity. *J Immunol.* 2008;181:4471–84. [PubMed: 18802050]
 22. Nian H, Shao H, O'Brien RL, Born WK, Kaplan HJ, Sun D. Activated $\gamma\delta$ cells promote the activation of uveitogenic T-cells and exacerbate EAU development. *Invest Ophthalmol Vis Sci.* 2011;52:5920–7. [PubMed: 21296823]
 23. Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D. IL-23 receptor expression on $\gamma\delta$ T-cells correlates with their enhancing or suppressive effects on autoreactive T-cells in experimental autoimmune uveitis. *J Immunol.* 2013;191:1118–25. [PubMed: 23797670]
 24. Liang D, Nian H, Shao H, Kaplan HJ, Sun D. Functional conversion and dominance of $\gamma\delta$ T subset in mouse experimental autoimmune uveitis. *J Immunol.* 2017;198:1429–38. [PubMed: 28069804]
 25. Liang D, Zuo A, Zhao R, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D. CD73 expressed on T-cells shapes their regulatory effect in experimental autoimmune uveitis. *PLoS One.* 2016;11:e0150078. [PubMed: 26919582]
 26. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, Moser B. A rapid crosstalk of human T-cells and monocytes drives the acute inflammation in bacterial infections. *PLoS Pathog.* 2009;5:e1000308. [PubMed: 19229322]
 27. Nian H, Shao H, Zhang G, Born WK, O'Brien RL, Kaplan HJ, Sun D. Regulatory effect of T-cells on IL-17⁺ uveitogenic T-cells. *Invest Ophthalmol Vis Sci.* 2010;51:4661–7. [PubMed: 20375337]
 28. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis using attenuated cells of a T lymphocyte line reactive against myelin basic protein. *Nature.* 1981;292:60–1. [PubMed: 6974307]
 29. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L. Limited heterogeneity of T-cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell.* 1988;54:263–73. [PubMed: 2455603]
 30. Acha-Orbea H, Steinman L, McDevitt HO. T-cell receptors in murine autoimmune diseases. *Ann Rev Immunol.* 1989;7:371–405. [PubMed: 2653372]
 31. Sun D, Coleclough C, Hu X. Heterogeneity of rat encephalitogenic T-cells elicited by variants of the MBP(68–88) peptide. *Eur J Immunol.* 1995;25:1687–92. [PubMed: 7542200]
 32. Myers LK, Stuart JM, Kang AH. A CD4 cell is capable of transferring suppression of collagen-induced arthritis. *J Immunol.* 1989;143:3976–80. [PubMed: 2574207]
 33. Gustafsson K, Karlsson M, Andersson L, Holmdahl R. Structures on the I-A molecule predisposing for susceptibility to type II collagen-induced autoimmune arthritis. *Eur J Immunol.* 1990;20:2127–31. [PubMed: 2209706]
 34. Caspi RR, Roberge FG, McAllister CG, el-Saied M, Kuwabara T, Gery I, Hanna E, Nussenblatt RB. T-cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. *J Immunol.* 1986;136:928–33. [PubMed: 2416842]
 35. Shao H, Peng Y, Liao T, Wang M, Song M, Kaplan HJ, Sun D. A shared epitope of the interphotoreceptor retinoid-binding protein recognized by the CD4⁺ and CD8⁺ autoreactive T-cells. *J Immunol.* 2005;175:1851–7. [PubMed: 16034128]
 36. Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D. Characterization of IL-17⁺ interphotoreceptor retinoid-binding protein-specific T-cells in experimental autoimmune uveitis. *Invest Ophthalmol Vis Sci.* 2007;48:4153–61. [PubMed: 17724201]

37. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. *Nat Med.* 2007;13:711–8. [PubMed: 17496900]
38. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. *J Exp Med.* 2008;205: 799–810. [PubMed: 18391061]
39. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1 β and 6 but not transforming growth factor- β are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol.* 2007;8:942–9. [PubMed: 17676045]
40. Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T-cell activation state characterized by the production of interleukin-17. *J Biol Chem.* 2003;278:1910–4. [PubMed: 12417590]
41. Bouguermouh S, Fortin G, Baba N, Rubio M, Sarfati M. CD28 co-stimulation down regulates Th17 development. *PLoS One.* 2009;4:e5087. [PubMed: 19333372]
42. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4⁺ T-cells. *Proc Natl Acad Sci U S A.* 2009;106:876–81. [PubMed: 19136631]
43. Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CM. Low-strength T-cell activation promotes Th17 responses. *Blood.* 2010;116:4829–37. [PubMed: 20713963]
44. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. *J Exp Med.* 2007;204:1849–61. [PubMed: 17635957]
45. O'Connor RA, Malpass KH, Anderton SM. The inflamed central nervous system drives the activation and rapid proliferation of Foxp3⁺ regulatory T-cells. *J Immunol.* 2007;179:958–66. [PubMed: 17617587]
46. Dong C Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. *Nat Rev Immunol.* 2006;6:329–34. [PubMed: 16557264]
47. Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol.* 2006;18:349–56. [PubMed: 16616472]
48. Weaver CT, Harrington LE, Mangan PR, Gavioli M, Murphy KM. Th17: an effector CD4 T-cell lineage with regulatory T-cell ties. *Immunity.* 2006;24:677–88. [PubMed: 16782025]
49. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T-cell from genesis through pathogenesis. *Cell.* 1993;74:1089–100. [PubMed: 8402882]
50. Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM. Transgenic mice that express a myelin basic protein-specific T-cell receptor develop spontaneous autoimmunity. *Cell.* 1993;72:51–56. [PubMed: 8422682]
51. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T-cells: mechanisms of differentiation and function. *Ann Rev Immunol.* 2012;30:531–64. [PubMed: 2224781]
52. Bluestone JA, Bour-Jordan H, Cheng M, Anderson M. T-cells in the control of organ-specific autoimmunity. *J Clin Invest.* 2015;125:225060.
53. Cui Y, Shao H, Lan C, Nian H, O'Brien RL, Born WK, Kaplan HJ, Sun D. Major role of T-cells in the generation of IL-17⁺ uveitogenic T-cells. *J Immunol.* 2009;183:560–7. [PubMed: 19542467]
54. Cheng L, Cui Y, Shao H, Han G, Zhu L, Huang Y, O'Brien RL, Born WK, Kaplan HJ, Sun D. Mouse T-cells are capable of expressing MHC class II molecules, and of functioning as antigen-presenting cells. *J Neuroimmunol.* 2008;203:3–11. [PubMed: 18774183]
55. Do J, Visperas A, Freeman ML, Jang E, Kim S, Malissen B, Min B. $\gamma\delta$ T-cells support gut Ag-reactive colitogenic effector T-cell generation by enhancing Ag presentation by CD11b⁺ DCs in the mesenteric LN. *Eur J Immunol.* 2006;46:340–6.
56. Huang Y, Yang Z, Huang C, McGowan J, Casper T, Sun D, Born WK, O'Brien RL. $\gamma\delta$ T-cell-dependent regulatory T-cells prevent the development of autoimmune keratitis. *J Immunol.* 2015;195:5572–81. [PubMed: 26566677]

57. Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, Sun D. Retinoic acid inhibits CD25+ dendritic cell expansion and $\gamma\delta$ T-cell activation in experimental autoimmune uveitis. *Invest Ophthalmol. Vis Sci.* 2013;54:3493–503. [PubMed: 23611991]
58. Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D. Roles of the adenosine receptor and CD73 in the regulatory effect of $\gamma\delta$ T-cells. *PLoS One.* 2014;9:e108932. [PubMed: 25268760]
59. Liang D, Zuo A, Shao H, Chen M, Kaplan HJ, Sun D. Anti- or pro-inflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environmental-dependent. *J Immunol.* 2014;193: 5498–505. [PubMed: 25367119]
60. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immuno-suppressive strategies that are mediated by tumor cells. *Ann Rev Immunol.* 2007;25 267–96. [PubMed: 17134371]
61. Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. *Trends Immunol.* 2012;33:231–7. [PubMed: 22487321]
62. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. *Cancer Res.* 2010;70:2245–55. [PubMed: 20179192]
63. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. *Cancer Res.* 2011;71:2892–900. [PubMed: 21292811]
64. Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. *Trends Mol Med.* 2013;19: 355–67. [PubMed: 23601906]
65. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. *Ann Rev Immunol.* 2004;22:657–82. [PubMed: 15032592]
66. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov.* 2008;7: 759–70. [PubMed: 18758473]
67. Liang D, Zuo A, Zhao R, Shao H, Kaplan HJ, Sun D. Regulation of adenosine deaminase on induced mouse experimental autoimmune uveitis. *J Immunol.* 2016;196:2646–54. [PubMed: 26856700]
68. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature.* 2001;414:916–20. [PubMed: 11780065]
69. Haskó G, Csóka B, Németh ZH, Vizi ES, Pacher P. A2B adenosine receptors in immunity and inflammation. *Trends Immunol.* 2009;30:263–70. [PubMed: 19427267]
70. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: critical role for A2A adenosine receptors in the T-cell-mediated regulation of colitis. *J Immunol.* 2006;177:2765–9. [PubMed: 16920910]
71. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, Drake CG, Powell JD. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T-cells. *Blood.* 2008;111:251–9. [PubMed: 17909080]
72. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. *N Engl J Med.* 2011;364:656–65. [PubMed: 21323543]
73. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, Ferrari V, Insel PA, Junger WG. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. *FASEB J.* 2009;23:1685–93. [PubMed: 19211924]
74. Woehrle T, Yip L, Elkhail A, Sumi Y, Chen Y, Yao Y, Insel PA, Junger WG. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. *Blood.* 2010;116:3475–84. [PubMed: 20660288]
75. Beigi RD, Kertesz SB, Aquilina G, Dubyak GR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. *Br J Pharmacol.* 2003;140:507–19. [PubMed: 14522842]
76. Canaday DH, Beigi R, Silver RF, Harding CV, Boom WH, Dubyak GR. ATP and control of intracellular growth of mycobacteria by T-cells. *Infect Immun.* 2002;70:6456–9. [PubMed: 12379727]

77. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B. The P2Y₁₁ receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. *J Immunol.* 2001;166:7172–7. [PubMed: 11390464]
78. Hanley PJ, Musset B, Renigunta V, Limberg SH, Dalpke AH, Sus R, Heeg KM, Preisig-Müller R, Daut J. Extracellular ATP induces oscillations of intracellular Ca²⁺ and membrane potential and promotes transcription of IL-6 in macrophages. *Proc Natl Acad Sci U S A.* 2004;101:9479–84. [PubMed: 15194822]
79. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, Waldmann H. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF- β . *Eur J Immunol.* 2011;41:2955–65. [PubMed: 21770045]
80. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, Kanellopoulos J, Quesniaux VF, Marchand-Adam S, Crestani B, Ryffel B, Couillin I. Extracellular ATP is a danger signal activating P2X₇ receptor in lung inflammation and fibrosis. *Amer J Res Crit Care Med.* 2010;182:774–83.
81. Beigi R, Kobatake E, Aizawa M, Dubyak GR. Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. *Am J Physiol.* 1999;276:C267–78. [PubMed: 9886943]
82. Sitkovsky MV, Ohta A. The “danger” sensors that STOP the immune response: the A₂ adenosine receptors? *Trends Immunol.* 2005;26:299–304. [PubMed: 15922945]
83. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T-cells mediates immune suppression. *J Exp Med.* 2007;204:1257–65. [PubMed: 17502665]
84. Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET. Adora2b adenosine receptor engagement enhances regulatory T-cell abundance during endotoxin-induced pulmonary inflammation. *PLoS One.* 2012;7:e32416. [PubMed: 22389701]
85. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL. Generation and accumulation of immunosuppressive adenosine by human CD4⁺CD25^{high}FOXP3⁺ regulatory T-cells. *J Biol Chem.* 2010;285:7176–86. [PubMed: 19858205]
86. Born W, Cady C, Jones-Carson J, Mukasa A, Lahn M, O’Brien R. Immunoregulatory functions of T-cells. *Adv Immunol.* 1999;71:77–144. [PubMed: 9917911]
87. Hayday A, Geng L. Gamma delta cells regulate autoimmunity. *Curr Opin Immunol.* 1997;9:884–9. [PubMed: 9492993]
88. Hayday AC. Gamma delta cells: a right time and a right place for a conserved third way of protection. *Ann Rev Immunol.* 2000;18:975–1026. [PubMed: 10837080]
89. Barankiewicz J, Ronlov G, Jimenez R, Gruber HE. Selective adenosine release from human B but not T lymphoid cell line. *J Biol Chem.* 1990;265:15738–43. [PubMed: 2394745]
90. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A₂B receptors. *J Exp Med.* 2003;198:783–96. [PubMed: 12939345]
91. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. *J Clin Invest.* 1986;78:760–70. [PubMed: 3745437]
92. Lappas CM, Rieger JM, Linden J. A₂A adenosine receptor induction inhibits IFN- γ production in murine CD4⁺ T-cells. *J Immunol.* 2005;174:1073–80. [PubMed: 15634932]
93. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, Norgauer J. Expression and function of adenosine receptors in human dendritic cells. *FASEB J.* 2001;15:1963–70. [PubMed: 11532976]
94. Hoskin DW, Mader JS, Furlong SJ, Conrad DM, Blay J. Inhibition of T-cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. *Int J Oncol.* 2008;32:527–35. [PubMed: 18292929]

95. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.* 2001;53:527–52. [PubMed: 11734617]
96. Varani K, Gessi S, Dalpiaz A, Borea PA. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. *Br J Pharmacol.* 1996;117:1693–701. [PubMed: 8732278]
97. Junger WG. Immune cell regulation by autocrine purinergic signalling. *Nat Rev Immunol.* 2011;11:201–12. [PubMed: 21331080]
98. Zaynagetdinov R, Ryzhov S, Goldstein AE, Yin H, Novitskiy SV, Goleniewska K, Polosukhin VV, Newcomb DC, Mitchell D, Morschl E, Zhou Y, Blackburn MR, Peebles RS, Jr, Biaggioni I, Feoktistov I. Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. *Am J Resp Cell Mol Biol.* 2010;42 564–71.
99. Kolachala V, Ruble B, Vijay-Kumar M, Wang L, Mwangi S, Figler H, Figler R, Srinivasan S, Gewirtz A, Linden J, Merlin D, Sitaraman S. Blockade of adenosine A2B receptors ameliorates murine colitis. *Brit J Pharmacol.* 2008;155:127–37. [PubMed: 18536750]
100. Belikoff BG, Vaickus LJ, Sitkovsky M, Remick DG. A2B adenosine receptor expression by myeloid cells is proinflammatory in murine allergic-airway inflammation. *J Immunol.* 2012;189:3707–13. [PubMed: 22956582]
101. Aydinug MK, Roark CL, Chain JL, Born WK, O'Brien RL. Macrophages express multiple ligands for TCRs. *Mol Immunol.* 2008;45:3253–63. [PubMed: 18455236]
102. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human T-cells by monocytes infected with live *Mycobacterium tuberculosis*. *J Clin Invest.* 1991;87:729–33. [PubMed: 1899430]
103. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V γ 9V δ 2 T-cells by NKG2D. *J Immunol.* 2005;175:2144–51.
104. Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human T lymphocytes. *J Immunol.* 2006;176:1348–54. [PubMed: 16424161]
105. Blackburn MR, Vance CO, Morschl E, Wilson CN. Adenosine receptors and inflammation In: Wilson CN, Mustafa SJ, editors. *Adenosine receptors in health and disease*. Berlin: Springer-Verlag; 2009 p. 215–269.
106. Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaïwa K, Otaka M, Watanabe S, Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. *Gastroenterol.* 2005;129:26–33.
107. Alam MS, Kurtz CC, Wilson JM, Burnette BR, Wiznerowicz EB, Ross WG, Rieger JM, Figler RA, Linden J, Crowe SE, Ernst PB. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T-cells and regulates *Helicobacter*-induced gastritis and bacterial persistence. *Mucosal Immunol.* 2009;2:232–42. [PubMed: 19262506]
108. Hirschhorn R, Grossman J, Weissmann G. Effect of cyclic 3',5'-adenosine monophosphate and theophylline on lymphocyte transformation. *Proc Soc Exp Biol Med.* 1970;133:1361–5. [PubMed: 4314861]
109. Polmar SH, Stern RC, Schwartz AL, Wetzler EM, Chase PA, Hirschhorn R. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. *N Engl J Med.* 1976;295: 1337–43. [PubMed: 980079]
110. Conter LJ, Song E, Shlomchik MJ, Tomayko MM. CD73 expression is dynamically regulated in the germinal center and bone marrow plasma cells are diminished in its absence. *PLoS One.* 2014;9:e92009. [PubMed: 24664100]
111. Tóth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch P, Degen O, Lohse AW, Eiermann T, Fätkenheuer G, Meyer-Olson D, Bockhorn M, Hauber J, van Lunzen J, Schulze Zur Wiesch J. Decreased frequency of CD73+CD8+ T-cells of HIV-infected patients correlates with immune activation and T-cell exhaustion. *J Leuk Biol.* 2013;4:551–61.

112. Thompson LF. Editorial: CD73 deficiency and immune dysregulation in HIV infection: cause or effect? *J Leuk Biol.* 2013;94:545–7.
113. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC. CD39 and control of cellular immune responses. *Purinergic Signal.* 2007;3:171–80. [PubMed: 18404431]
114. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Röttschke O, Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. *Blood.* 2007;110:1225–32. [PubMed: 17449799]
115. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T-cell biology. *J Immunol.* 2010;185:1993–8. [PubMed: 20686167]
116. Apasov SG, Chen JF, Smith PT, Schwarzschild MA, Fink JS, Sitkovsky MV. Study of A2A adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A2A receptor-unrelated lymphotoxicity. *Brit J Pharmacol.* 2000;131:43–50. [PubMed: 10960067]
117. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discov.* 2006;5:247–64. [PubMed: 16518376]
118. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase (ADA)-deficiency. *Front Immunol.* 2012;3: 265–75. [PubMed: 22969765]
119. Notarangelo LD, Stoppoloni G, Toraldo R, Mazzolari E, Coletta A, Airò P, Bordignon C, Ugazio AG. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. *Eur J Pediatr.* 1992;151:811–4. [PubMed: 1468454]
120. Ozsahin H, Arredondo-Vega FX, Santisteban I, Fuhrer H, Tuchschild P, Jochum W, Aguzzi A, Lederman HM, Fleischman A, Winkelstein JA, Seger RA, Hershfield MS. Adenosine deaminase deficiency in adults. *Blood.* 1997;89:2849–55. [PubMed: 9108404]
121. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV. Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T-cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. *Mol Pharmacol.* 1999;55:614–24. [PubMed: 10051547]
122. Wilson JM, Kurtz CC, Black SG, Ross WG, Alam MS, Linden J, Ernst PB. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. *J Immunol.* 2011;186:6746–52. [PubMed: 21593380]
123. Vincenzi F, Padovan M, Targa M, Corciulo C, Giacuzzo S, Merighi S, Gessi S, Govoni M, Borea PA, Varani K. A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. *PLoS One.* 2013;8:e54195. [PubMed: 23326596]
124. Ben Addi A, Lefort A, Hua X, Libert F, Communi D, Ledent C, Macours P, Tilley SL, Boeynaems JM, Robaye B. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A2B receptor. *Eur J Immunol.* 2008;38:1610–20. [PubMed: 18465770]
125. Csóka B, Selmeczy Z, Koscsó B, Németh ZH, Pacher P, Murray PJ, Kepka-Lenhart D, Morris SM, Jr, Gause WC, Leibovich SJ, Haskó G. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. *FASEB J.* 2012;26:376–86. [PubMed: 21926236]
126. McColl SR, St-Onge M, Dussault AA, Laflamme C, Bouchard L, Boulanger J, Pouliot M. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. *FASEB J.* 2006;20:187–9. [PubMed: 16280366]
127. Manohar M, Hirsh MI, Chen Y, Woehrle T, Karande AA, Junger WG. ATP release and autocrine signaling through P2X4 receptors regulate $\gamma\delta$ T-cell activation. *J Leuk Biol.* 2012;92:787–94.
128. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. *Blood.* 1997;90:1600–10. [PubMed: 9269779]
129. Dieli F, Ivanyi J, Marsh P, Williams A, Naylor I, Sireci G, Caccamo N, Di Sano C, Salerno A. Characterization of lung T-cells following intranasal infection with *Mycobacterium bovis* bacillus Calmette-Guérin. *J Immunol.* 2003;170:463–9. [PubMed: 12496432]

130. Belles C, Kuhl AK, Donoghue AJ, Sano Y, O'Brien RL, Born W, Bottomly K, Carding SR. Bias in the T-cell response to *Listeria monocytogenes*. V delta 6.3+ cells are a major component of the gamma delta T-cell response to *Listeria monocytogenes*. *J Immunol*. 1996;156: 4280–9. [PubMed: 8666799]
131. Naiki Y, Nishimura H, Itohara S, Yoshikai Y. Gamma delta T-cells may dichotomously modulate infection with avirulent *Salmonella choleraesuis* via IFN- γ and IL-13 in mice. *Cell Immunol*. 2000;202:61–9. [PubMed: 10873307]
132. Ninomiya T, Takimoto H, Matsuzaki G, Hamano S, Yoshida H, Yoshikai Y, Kimura G, Nomoto K. V γ 1+ γ 8 T-cells play protective roles at an early phase of murine cytomegalovirus infection through production of interferon- γ . *Immunol*. 2000;99:187–94.
133. Huber SA, Moraska A, Choate M. T-cells expressing the gamma delta T-cell receptor potentiate coxsackievirus B3-induced myocarditis. *J Virol*. 1992;66:6541–6. [PubMed: 1328680]
134. Hou S, Katz JM, Doherty PC, Carding SR. Extent of gd T-cell involvement in the pneumonia caused by Sendai virus. *Cell Immunol*. 1992;143:183–93. [PubMed: 1320465]